Cas:83140-94-7 (3-pyrrol-1-ylphenyl)methanol manufacturer & supplier

We serve Chemical Name:(3-pyrrol-1-ylphenyl)methanol CAS:83140-94-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(3-pyrrol-1-ylphenyl)methanol

Chemical Name:(3-pyrrol-1-ylphenyl)methanol
CAS.NO:83140-94-7
Synonyms:3-(pyrrol-1-yl)phenylmethanol;3-(1-pyrrolyl)benzyl alcohol;(3-pyrrolylphenyl)methan-1-ol;3-pyrrol-1-ylbenzyl alcohol;[3-(1H-Pyrrol-1-yl)phenyl]methanol
Molecular Formula:C11H11NO
Molecular Weight:173.21100
HS Code:2933990090

Physical and Chemical Properties:
Melting point:70ºC
Boiling point:334.7ºC at 760 mmHg
Density:1.07g/cm3
Index of Refraction:1.573
PSA:25.16000
Exact Mass:173.08400
LogP:1.96960

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-(pyrrol-1-yl)phenylmethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[3-(1H-Pyrrol-1-yl)phenyl]methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(1-pyrrolyl)benzyl alcohol Use and application,(3-pyrrolylphenyl)methan-1-ol technical grade,usp/ep/jp grade.


Related News: Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. (3-pyrrol-1-ylphenyl)methanol manufacturer Covington has handled dozens of cases for Lilly over the past 20 years, according to the Westlaw database of legal cases and press releases, including intellectual property matters, personal injury lawsuits and class actions. (3-pyrrol-1-ylphenyl)methanol supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. (3-pyrrol-1-ylphenyl)methanol vendor With the death toll surging past 300 and 14,300 cases confirmed, authorities across the country have activated the highest public health emergency response, stepping up screening of arrivals from Wuhan. (3-pyrrol-1-ylphenyl)methanol factory Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.